MODEL VERDICT
Arvinas, Inc. (ARVN)
Relative Valuation•Peer multiples, competitive benchmarking & quality-adjusted fair value
The market is pricing Arvinas, Inc. at a 63.01% premium to its peer-implied fair value.
14 industry peers matched by industry sector due to narrow curated coverage
| Ticker | Company | Market Cap | P/E | EV/EBITDA |
|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Incorporated | $128.97B | 33.17x | 25.72x |
| REGN | Regeneron Pharmaceuticals, Inc. | $80.86B | 18.92x | 19.52x |
| ARGX | argenx SE | $63.79B | 50.45x | 55.77x |
| ALNY | Alnylam Pharmaceuticals, Inc. | $31.98B | 102.82x | 56.72x |
| RPRX | Royalty Pharma plc | $25.89B | 32.45x | 21.89x |
| INCY | Incyte Corporation | $25.4B | 19.55x | 15.58x |
| BNTX | BioNTech SE | $24.13B | -18.56x | - |
| GMAB | Genmab A/S | $21.33B | 22.56x | 18.94x |
| UTHR | United Therapeutics Corporation | $21B | 17.75x | 12.15x |
| JAZZ | Jazz Pharmaceuticals plc | $15.12B | -41.22x | 24.99x |
| ASND | Ascendis Pharma A/S | $14.7B | -56.98x | - |
| EXEL | Exelixis, Inc. | $14.67B | 20.99x | 15.93x |
1 valuation metric · peer-median based
| Multiple | Current | Peer Median | vs Peers | Implied Price |
|---|---|---|---|---|
| P/EPrice paid for current earnings. | 58.55x | 22.56x | Premium +159.53% | $3.19 |
How the model derives the final fair value from peer baselines and quality metrics
Premium: The stock is trading at a 170.7% premium to its quality-adjusted fair value of $3.06. The market is pricing the stock 63.06% above our model's estimate.
Quality metrics are broadly comparable to peers.
Quality adjustments are capped at ±15% (up to ±20% for financial services) to prevent runaway premiums. Based on trailing twelve months and multi-year CAGR data where available.
Wall Street target prices — 26 analysts
Model-identified caveats to consider
ARVN has a limited relative valuation using industry peers; based mainly on P/E, it looks expensive versus peers.
Answers to common questions about ARVN's relative valuation and our methodology.
Arvinas, Inc.'s fair value of $3.07 is the price at which the stock would trade if valued at the same multiples as its 14-company peer group, adjusted for differences in business quality. At $8.29, the stock trades at a -62.97% premium to fair value. This is a reference point, not a price target.
Peers were grouped by industry classification and market capitalization. The 14 companies shown are the closest comparable names with clean, usable financial data.
Arvinas, Inc. has strengths in 3y revenue growth, and challenges in roic, fcf margin, and a quality score that warrants a 4% discount relative to its peer group. The Quality Adjustment section breaks down each driver.
No. This page provides an automated quantitative comparison of Arvinas, Inc. against its peers. It is not investment advice, a recommendation, or a solicitation. Valuation is only one factor in an investment decision — it does not account for growth catalysts, management quality, regulatory risk, or your personal financial situation.
A 62.97% premium is substantial. Large premiums suggest the market is pricing in significant growth or quality advantages that must be delivered to justify the current price. Review the Risk Factors and Historical Context sections to assess whether the gap is justified.
Valuation data is refreshed weekly based on the latest financial filings, market prices, and analyst estimates. Arvinas, Inc.'s fair value, peer multiples, and quality scores will shift over time as new earnings are reported and stock prices change.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. Fair value estimates are model outputs under stated assumptions and should not be relied upon as the sole basis for any investment decision.